摘要:
According to the present invention, a recombinant DNA wherein a DNA coding for a novel physiologically active polypeptide produced by human erythroleukemia cell strain K562-T1 is incorporated and a microorganism or an animal cell carrying the recombinant DNA can be obtained, and they can be utilized for producing a large amount of the physiologically active polypeptide.
摘要:
Triglycerides in a sample are quantitatively determined using a test composition having a system for converting the triglycerides to fatty acids and glycerol, a system for oxidizing the glycerol, and a system for determining the amount of oxygen consumed or the amount of hydrogen peroxide or glyceraldehyde formed in the oxidation of the glycerol.
摘要:
Disclosed is a process for producing a staurosporine derivative represented by Formula (I):
wherein: Q represents hydrogen or
-X-(CH₂) m -Y-(CH₂) n -Z
or a pharmaceutically acceptable salt thereof, which comprises oxidizing a compound represented by Formula (II)
wherein Q has the same meaning as previously defined,with dimethylsulfoxide (DMSO) and an aqueous alkaline solution. Also, disclosed is a novel staurosporine derivative represented by the formula (I) wherein Q is
-X-(CH₂) m -Y-(CH₂)₄-Z
The staurosporine derivative (I) possesses selective protein kinase C-inhibitory and cell growth-inhibiting activities, and platelet-increasing activity.
摘要:
According to the present invention, a recombinant DNA wherein a DNA coding for a novel physiologically active polypeptide produced by human erythroleukemia cell strain K562-T1 is incorporated and a microorganism or an animal cell carrying the recombinant DNA can be obtained, and they can be utilized for producing a large amount of the physiologically active polypeptide.